You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1581 - 1590 of 10165 results
  1. Development of a Non-invasive Negative Ophthalmodynamometer Capable of Measuring Intracranial Pressure in Humans

    SBC: Equinox Ophthalmic, Inc.            Topic: CBD192005

    Measurement of intracranial pressure (ICP) is essential in the diagnosis and management of numerous life threatening conditions. All current methods used clinically to measure ICP are invasive and require direct access to the cerebrospinal fluid giving them a significant side effect profile. The ability to measure ICP non-invasively would be a major milestone for patients. Spontaneous venous pulsa ...

    SBIR Phase I 2020 Department of DefenseOffice for Chemical and Biological Defense
  2. Development of Small Molecule Therapeutics for Emerging Viral Agents

    SBC: ARISAN THERAPEUTICS INC            Topic: CBD192006

    Arenaviruses comprise a diverse group of Old (Africa) and New World (Americas) species. Several species are associated with hemorrhagic fever (HF) with case-fatality rates as high as 30%. Arenaviruses infection typically occurs via the mucosal route through contact with excretions of an infected rodents although direct human-to-human transmission may occur in clinical settings. Lassa arenavirus en ...

    SBIR Phase I 2020 Department of DefenseOffice for Chemical and Biological Defense
  3. Development of Small Molecule Therapeutics for Emerging Viral Agents

    SBC: ARISAN THERAPEUTICS INC            Topic: CBD192006

    Ebolavirus species including Zaire (EBOV), Sudan (SUDV) and Bundibugyo (BDBV) are responsible for severe hemorrhagic fever outbreaks with high case fatalities in Africa. Weaponized pathogens present an additional threat to the health protection of the warfighter and first-generation prophylactic and therapeutic medical countermeasures (MCMs) may prove inadequate in biodefense settings. Ebolaviruse ...

    SBIR Phase I 2020 Department of DefenseOffice for Chemical and Biological Defense
  4. Optimized Platforms for Proper Glycosylation and Sialylation of Recombinant Human Butyrylcholinesterase (rBChE)

    SBC: Technology Holding, LLC            Topic: CBD192007

    The threat of organophosphate (OP) chemical warfare agents (CWA) to United States military personnel is a persistent problem due to the relative ease of manufacturing chemical threats compared to nuclear and biological agents. Human butyrylcholinesterase (BChE) has been identified as a probable bio-scavenger of OP CWAs that could be used to protect individuals that could be exposed to OP CWAs. The ...

    SBIR Phase I 2020 Department of DefenseOffice for Chemical and Biological Defense
  5. Optimized Platforms for Proper Glycosylation and Sialylation of Recombinant Human Butyrylcholinesterase (rBChE)

    SBC: ECHELON BIOSCIENCES, INC.            Topic: CBD192007

    Organophosphorus (OP) toxins and chemical warfare agents (CWA) are active nerve agents posing significant hazard for both soldiers and civilians. Butyrylcholinesterase (BChE) is a safe and effective bioscavenger that detoxifies OP and CWAs when injected either prophylactically or post-exposure; but a major technical problem has been producing a recombinant form of BChE with acceptable properties f ...

    SBIR Phase I 2020 Department of DefenseOffice for Chemical and Biological Defense
  6. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  7. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  8. Field-Usable Designer Drug Analyzer

    SBC: REAL-TIME ANALYZERS INC            Topic: CBD181006

    While this solicitation described the need for better sampling methods and rugged mass spectrometers, the topic author funded our alternative approach, which employs existing DoD Raman spectrometers. The Phase III project goal is to develop a Field-Usable Designer Drug Analyzer capable of identifying and quantifying drugs in saliva and blood at 10 ng/mL in 10 minutes. Feasibility was demonstrated ...

    SBIR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  9. THE PRIMARY OBJECTIVE OF THE PROPOSED PHASE II WORK IS TO EXPAND THE PRODUCT OFFERING AND SUCCESSFULLY COMMERCIALIZE THE MVP THAT WAS SUCCESSFULLY DEV

    SBC: S-3 RESEARCH LLC            Topic: 166

    To transition the AI-based POC into a minimum viable product (MVP) that continually collects data from multiple social media platforms to detect illicit online opioid sales

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. TOPIC 397- MICROFLUIDIC VORTEX SHEDDING: A LOW-COST, HIGH EFFICIENCY METHOD FOR GENETIC MODIFICATION TO SUPPORT CELL ENGINEERING FOR CELL-BASED IMMUN

    SBC: Indee. Inc.            Topic: 397

    Personalized gene-modified cell immunotherapies exist, but manufacturing has yet to be optimized to increase the broad availability of these life-saving therapies to patients in need. This proposal is focused on meeting this need with the continued development of microfluidic vortex shedding (μVS), a safe and rapid approach to genetically modify patient-derived immune cells. The long term objecti ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government